Interference of ALOX5 alleviates inflammation and fibrosis in high glucose‑induced renal mesangial cells

Chen,Xiaotao; Xie,Hongwu; Liu,Yun; Ou,Qiujuan; Deng,Shuaijie

doi:10.3892/etm.2022.11733

Interference of ALOX5 alleviates inflammation and fibrosis in high glucose‑induced renal mesangial cells

Authors:
- Xiaotao Chen
- Hongwu Xie
- Yun Liu
- Qiujuan Ou
- Shuaijie Deng
View Affiliations

Affiliations: Department of Endocrinology, Affiliated Hospital of Xiangnan University, Chenzhou, Hunan 423000, P.R. China, Department of Endocrinology, The Fourth People's Hospital of Chenzhou, Chenzhou, Hunan 423001, P.R. China, Department of Nephrology, Affiliated Hospital of Xiangnan University, Chenzhou, Hunan 423000, P.R. China, Century College, Beijing University of Posts and Telecommunications, Beijing 102101, P.R. China
Published online on: November 28, 2022 https://doi.org/10.3892/etm.2022.11733
Article Number: 34
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic nephropathy (DN) is the leading cause of end‑stage renal disease (ESRD), seriously threatening the health of individuals. The 5‑lipoxygenase (ALOX5) gene has been reported to be associated with diabetes, but whether it is involved in DN remains unclear. The present study aimed to explore the role of ALOX5 in DN and to clarify the potential mechanism. Mouse renal mesangial cells (SV40 MES‑13) were treated with high glucose (HG) to mimic a DN model in vitro. The expression level of ALOX5 was assessed using reverse transcription‑quantitative PCR and western blotting. Cell Counting Kit‑8 and flow cytometric assays were performed to determine cell proliferation, the cell cycle and apoptosis. Immunofluorescence was carried out to detect the expression of Ki67 and proliferating cell nuclear antigen (PCNA). The inflammatory cytokines were assessed using ELISA. The expression of fibrosis‑ and NF‑κB‑related proteins was determined using western blotting. The results revealed that ALOX5 was significantly upregulated in HG‑induced SV40 MES‑13 cells. Interference of ALOX5 greatly hindered HG‑induced cell viability loss, as well as increasing the expression of Ki67 and PCNA. In addition, HG induced cell cycle arrest in the G1 phase and cell apoptosis, which were then partly abolished by interference of ALOX5. Moreover, the elevated production of inflammatory cytokines and upregulated fibrosis‑related proteins induced by HG were weakened by interference of ALOX5. Eventually, interference of ALOX5 was found to reduce the activity of NF‑κB signaling in HG‑induced SV40 MES‑13 cells. Collectively, interference of ALOX5 serves as a protective role in HG‑induced kidney cell injury, providing a potential therapeutic strategy of DN treatment.

View Figures

View References

1	Sagoo MK and Gnudi L: Diabetic nephropathy: An overview. Methods Mol Biol. 2067:3–7. 2020.PubMed/NCBI View Article : Google Scholar
2	Gheith O, Farouk N, Nampoory N, Halim MA and Al-Otaibi T: Diabetic kidney disease: World wide difference of prevalence and risk factors. J Nephropharmacol. 5:49–56. 2016.PubMed/NCBI
3	Narres M, Claessen H, Droste S, Kvitkina T, Koch M, Kuss O and Icks A: The incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: A systematic review. PLoS One. 11(e0147329)2016.PubMed/NCBI View Article : Google Scholar
4	Si X, Li P, Zhang Y, Zhang Y, Lv W and Qi D: Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats. Biomed Rep. 2:24–28. 2014.PubMed/NCBI View Article : Google Scholar
5	Shi Y and Hu FB: The global implications of diabetes and cancer. Lancet. 383:1947–1948. 2014.PubMed/NCBI View Article : Google Scholar
6	Weir MA and Herzog CA: Beta blockers in patients with end-stage renal disease-evidence-based recommendations. Semin Dial. 31:219–225. 2018.PubMed/NCBI View Article : Google Scholar
7	Dobrian AD, Lieb DC, Cole BK, Taylor-Fishwick DA, Chakrabarti SK and Nadler JL: Functional and pathological roles of the 12- and 15-lipoxygenases. Prog Lipid Res. 50:115–131. 2011.PubMed/NCBI View Article : Google Scholar
8	Chen F, Ghosh A, Lin J, Zhang C, Pan Y, Thakur A, Singh K, Hong H and Tang S: 5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer's disease. Brain Behav Immun. 88:844–855. 2020.PubMed/NCBI View Article : Google Scholar
9	Wang Y, Skibbe JR, Hu C, Dong L, Ferchen K, Su R, Li C, Huang H, Weng H, Huang H, et al: ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia. Sci Rep. 7(1853)2017.PubMed/NCBI View Article : Google Scholar
10	Lisovyy OO, Dosenko VE, Nagibin VS, Tumanovska LV, Korol MO, Surova OV and Moibenko OO: Cardioprotective effect of 5-lipoxygenase gene (ALOX5) silencing in ischemia-reperfusion. Acta Biochim Pol. 56:687–694. 2009.PubMed/NCBI
11	Wu Y, Sun H, Song F, Huang C and Wang J: Deletion of Alox5 gene decreases osteogenic differentiation but increases adipogenic differentiation of mouse induced pluripotent stem cells. Cell Tissue Res. 358:135–147. 2014.PubMed/NCBI View Article : Google Scholar
12	Zhu L, Yang F, Wang L, Dong L, Huang Z, Wang G, Chen G and Li Q: Identification the ferroptosis-related gene signature in patients with esophageal adenocarcinoma. Cancer Cell Int. 21(124)2021.PubMed/NCBI View Article : Google Scholar
13	Tang J, Zhang C, Lin J, Duan P, Long J and Zhu H: ALOX5-5-HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation. Cancer Med. 10:5246–5255. 2021.PubMed/NCBI View Article : Google Scholar
14	Heemskerk MM, Giera M, Bouazzaoui FE, Lips MA, Pijl H, van Dijk KW and van Harmelen V: Increased PUFA content and 5-Lipoxygenase pathway expression are associated with subcutaneous adipose tissue inflammation in obese women with type 2 diabetes. Nutrients. 7:7676–7690. 2015.PubMed/NCBI View Article : Google Scholar
15	ul Ain Q, Greig NH, Nawaz MS, Rashid S and Kamal MA: Exploring N(1)-p-fluorobenzyl-cymserine as an inhibitor of 5-lipoxygenase as a candidate for type 2 diabetes and neurodegenerative disorder treatment. CNS Neurol Disord Drug Targets. 13:197–202. 2014.PubMed/NCBI View Article : Google Scholar
16	Ramalho T, Filgueiras L, Silva-Jr IA, Pessoa AFM and Jancar S: Impaired wound healing in type 1 diabetes is dependent on 5-lipoxygenase products. Sci Rep. 8(14164)2018.PubMed/NCBI View Article : Google Scholar
17	Schwartzman ML, Iserovich P, Gotlinger K, Bellner L, Dunn MW, Sartore M, Grazia Pertile M, Leonardi A, Sathe S, Beaton A, et al: Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy. Diabetes. 59:1780–1788. 2010.PubMed/NCBI View Article : Google Scholar
18	Gubitosi-Klug RA, Talahalli R, Du Y, Nadler JL and Kern TS: 5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy. Diabetes. 57:1387–1393. 2008.PubMed/NCBI View Article : Google Scholar
19	Landgraf SS, Silva LS, Peruchetti DB, Sirtoli GM, Moraes-Santos F, Portella VG, Silva-Filho JL, Pinheiro CS, Abreu TP, Takiya CM, et al: 5-Lypoxygenase products are involved in renal tubulointerstitial injury induced by albumin overload in proximal tubules in mice. PLoS One. 9(e107549)2014.PubMed/NCBI View Article : Google Scholar
20	Reinhold SW, Vitzthum H, Filbeck T, Wolf K, Lattas C, Riegger GA, Kurtz A and Krämer BK: Gene expression of 5-, 12-, and 15-lipoxygenases and leukotriene receptors along the rat nephron. Am J Physiol Renal Physiol. 290:F864–F872. 2006.PubMed/NCBI View Article : Google Scholar
21	Qi H, Yao L and Liu Q: NORAD affects the progression of diabetic nephropathy through targeting miR-520h to upregulate TLR4. Biochem Biophys Res Commun. 521:190–195. 2020.PubMed/NCBI View Article : Google Scholar
22	Du Y, Yang YT, Tang G, Jia JS, Zhu N and Yuan WJ: Butyrate alleviates diabetic kidney disease by mediating the miR-7a-5p/P311/TGF-beta1 pathway. FASEB J. 34:10462–10475. 2020.PubMed/NCBI View Article : Google Scholar
23	Yang X, Luo W, Li L, Hu X, Xu M, Wang Y, Feng J, Qian J, Guan X, Zhao Y and Liang G: CDK9 inhibition improves diabetic nephropathy by reducing inflammation in the kidneys. Toxicol Appl Pharmacol. 416(115465)2021.PubMed/NCBI View Article : Google Scholar
24	Xu J, Xiang P, Liu L, Sun J and Ye S: Metformin inhibits extracellular matrix accumulation, inflammation and proliferation of mesangial cells in diabetic nephropathy by regulating H19/miR-143-3p/TGF-β1 axis. J Pharm Pharmacol. 72:1101–1109. 2020.PubMed/NCBI View Article : Google Scholar
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
26	Jurikova M, Danihel L, Polak S and Varga I: Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 118:544–552. 2016.PubMed/NCBI View Article : Google Scholar
27	Liu T, Zhang L, Joo D and Sun SC: NF-κB signaling in inflammation. Signal Transduct Target Ther. 2(17023)2017.PubMed/NCBI View Article : Google Scholar
28	Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, Mora-Fernández C and Navarro-González JF: Inflammatory cytokines in diabetic nephropathy. J Diabetes Res. 2015(948417)2015.PubMed/NCBI View Article : Google Scholar
29	Samsu N: Diabetic nephropathy: Challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int. 2021(1497449)2021.PubMed/NCBI View Article : Google Scholar
30	Moreno JA, Gomez-Guerrero C, Mas S, Sanz AB, Lorenzo O, Ruiz-Ortega M, Opazo L, Mezzano S and Egido J: Targeting inflammation in diabetic nephropathy: A tale of hope. Expert Opin Investig Drugs. 27:917–930. 2018.PubMed/NCBI View Article : Google Scholar
31	Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC and Tesch GH: Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol. 16:1711–1722. 2005.PubMed/NCBI View Article : Google Scholar
32	Zheng H, Li X, Yang X, Yan F, Wang C and Liu J: miR-217/Mafb axis involve in high glucose-induced β-TC-tet cell damage via regulating NF-κB signaling pathway. Biochem Genet. 58:901–913. 2020.PubMed/NCBI View Article : Google Scholar
33	Dong J, Li H, Bai Y and Wu C: Muscone ameliorates diabetic peripheral neuropathy through activating AKT/mTOR signalling pathway. J Pharm Pharmacol. 71:1706–1713. 2019.PubMed/NCBI View Article : Google Scholar
34	Rane MJ, Song Y, Jin S, Barati MT, Wu R, Kausar H, Tan Y, Wang Y, Zhou G, Klein JB, et al: Interplay between Akt and p38 MAPK pathways in the regulation of renal tubular cell apoptosis associated with diabetic nephropathy. Am J Physiol Renal Physiol. 298:F49–F61. 2010.PubMed/NCBI View Article : Google Scholar
35	Yu Q, Zhang M, Qian L, Wen D and Wu G: Luteolin attenuates high glucose-induced podocyte injury via suppressing NLRP3 inflammasome pathway. Life Sci. 225:1–7. 2019.PubMed/NCBI View Article : Google Scholar
36	Ma J, Zhao N, Du L and Wang Y: Downregulation of lncRNA NEAT1 inhibits mouse mesangial cell proliferation, fibrosis, and inflammation but promotes apoptosis in diabetic nephropathy. Int J Clin Exp Pathol. 12:1174–1183. 2019.PubMed/NCBI
37	Liu G, Shea CM, Jones JE, Price GM, Warren W, Lonie E, Yan S, Currie MG, Profy AT, Masferrer JL and Zimmer DP: Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells. Am J Physiol Renal Physiol. 319:F697–F711. 2020.PubMed/NCBI View Article : Google Scholar
38	Oguiza A, Recio C, Lazaro I, Mallavia B, Blanco J, Egido J and Gomez-Guerrero C: Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes. Diabetologia. 58:1656–1667. 2015.PubMed/NCBI View Article : Google Scholar
39	Schröfelbauer B, Polley S, Behar M, Ghosh G and Hoffmann A: NEMO ensures signaling specificity of the pleiotropic IKKβ by directing its kinase activity toward IκBα. Mol Cell. 47:111–121. 2012.PubMed/NCBI View Article : Google Scholar
40	Manna K, Mishra S, Saha M, Mahapatra S, Saha C, Yenge G, Gaikwad N, Pal R, Oulkar D, Banerjee K and Das Saha K: Amelioration of diabetic nephropathy using pomegranate peel extract-stabilized gold nanoparticles: Assessment of NF-κB and Nrf2 signaling system. Int J Nanomedicine. 14:1753–1777. 2019.PubMed/NCBI View Article : Google Scholar
41	Zhang Y, Ren S, Ji Y and Liang Y: Pterostilbene ameliorates nephropathy injury in streptozotocin-induced diabetic rats. Pharmacology. 104:71–80. 2019.PubMed/NCBI View Article : Google Scholar
42	Kolati SR, Kasala ER, Bodduluru LN, Mahareddy JR, Uppulapu SK, Gogoi R, Barua CC and Lahkar M: BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway. Environ Toxicol Pharmacol. 39:690–699. 2015.PubMed/NCBI View Article : Google Scholar
43	Zhao Y, Wang W, Wang Q, Zhang X and Ye L: Lipid metabolism enzyme 5-LOX and its metabolite LTB4 are capable of activating transcription factor NF-κB in hepatoma cells. Biochem Biophys Res Commun. 418:647–651. 2012.PubMed/NCBI View Article : Google Scholar
44	Cheng JH, Zhang WJ, Zhu JF, Cui D, Song KD, Qiang P, Mei CZ, Nie ZC, Ding BS, Han Z, et al: CaMKIIγ regulates the viability and self-renewal of acute myeloid leukaemia stem-like cells by the Alox5/NF-κB pathway. Int J Lab Hematol. 43:699–706. 2021.PubMed/NCBI View Article : Google Scholar